CELLCEUTIX CORP COM STK USD0.0001 (CTIX)

0.95
OTC Markets
Prev Close 0.98
Day Low/High 0.94 / 0.98
52 Wk Low/High 0.86 / 1.92
Exchange OTC Markets
Shares Outstanding 126.41B
Market Cap 123.75M
Div & Yield N.A. (N.A)

Latest News

Cellceutix's Phase 2 Drug Candidate Brilacidin Emerging As A Potential Novel Non-Biologic Therapy In Treating Inflammatory Bowel Disease

Cellceutix's Phase 2 Drug Candidate Brilacidin Emerging As A Potential Novel Non-Biologic Therapy In Treating Inflammatory Bowel Disease

Study to help guide Cellceutix in continued development of Brilacidin, including planned foam and oral formulations for hard-to-treat chronic conditions like Ulcerative Colitis and Crohn's Disease

Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix

Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix

TheStreet's Adam Feuerstein answers readers' questions about biotech stocks.

Cellceutix Investors See Red Flags in Drug Study

Cellceutix Investors See Red Flags in Drug Study

Does Cellceutix have something to hide?

Biotech School: When Cellceutix CEO Rants About 'Criminal' Short, Smart Investors See Red Flags

Biotech School: When Cellceutix CEO Rants About 'Criminal' Short, Smart Investors See Red Flags

CEOs of troubled companies tend to launch public tirades against the 'evil' shorts. The rants are often a smokescreen meant to divert investors' attention from problems.

Cellceutix Announces Business Update Call At 10AM Eastern On November 15

Cellceutix Announces Business Update Call At 10AM Eastern On November 15

Management to provide Clinical, Regulatory and Financial Updates

Sophiris Bio Tops Dollar-Stock Gainers on Trial Success of Cancer Treatment

Shares of the urology company surge in postmarket trading Thursday.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Cellceutix Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Cellceutix Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...